Post-Doctoral Training Fellow - Computational Chemist/Molecular Modeller

09/02/2019, 23:55

Cancer Therapeutics
Medicinal Chemistry 1
Full time
Fixed Term
2 years
£31,023 -39,473
The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

Under the leadership of our Chief Executive, Professor Paul Workman FRS, the ICR is ranked as the UK’s leading academic research centre. Together with our partner The Royal Marsden, we are rated in the top four cancer centres globally.

The ICR is committed to attracting, developing and retaining the best minds in the world to join us in our mission – to make the discoveries that defeat cancer.

The Cancer Research UK Cancer Therapeutics Unit, part of the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The CR-UK Cancer Therapeutics Unit’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists.

A Post-Doctoral Training Fellow position in computational chemistry and molecular modelling is now available in our In Silico Medicinal Chemistry group. The successful candidate will be expected to learn and apply in silico medicinal chemistry techniques that impact across the CR-UK Cancer Therapeutics Unit portfolio of drug discovery projects. The candidate will provide close support to scientists in our Hit Discovery and Structural Design Team, and contribute to expand the capabilities of the In-Silico medicinal chemistry group.

Applicants must have a PhD, which may be in an area of molecular modelling, computational chemistry, or cheminformatics, with experience of application of computational techniques in drug discovery projects. Alternatively, applicants may have a PhD in medicinal chemistry or drug design with appropriate experience in the use of computational techniques.

Informal enquiries are welcome and can be made to Dr Mirco Meniconi ( Applications must be submitted online, via the e-recruitment system – please visit

We consider all applications on merit and have a strong commitment to enhancing the diversity of our staff.

In partnership with

Cancer Research UK
Additional Documentation for Candidates

This Program is closed to applications.